Background and Objectives In patients undergoing neuraxial anesthesia, heat loss and core-to-peripheral redistribution of body heat causes the core temperature to decrease. The shivering threshold is therefore reached soon, and more shivering is required to prevent further hypothermia. Because shivering has deleterious metabolic and cardiovascular effects, it should ideally be prevented by pharmacologic or other means. We evaluated the usefulness of intravenous (IV) nefopam and tramadol in preventing and reducing the severity of shivering in patients undergoing neuraxial anesthesia for orthopedic surgery.
Methods Ninety patients, scheduled for neuraxial anesthesia (epidural or subarachnoid) for lower limb orthopedic surgery, were prospectively enrolled. Patients were randomly assigned to 1 of 3 groups. Immediately before neuraxial anesthesia, 30 patients received 0.15 mg/kg−1 IV nefopam in 10 mL saline, 30 patients received 0.5 mg/kg−1 IV tramadol in 10 mL saline, and a control group of 30 patients received 10 mL IV saline. Neuraxial anesthesia was induced at the L3-L4 or L4-L5 interspaces with 1 mg/kg−1 mepivacaine for epidural anesthesia and 0.2 mg/kg−1 for subarachnoid anesthesia. An investigator blinded to the antishivering drug injected recorded the frequency and degree of shivering.
Results The overall frequency and the intensity of shivering was significantly lower in patients treated with nefopam than in those treated with tramadol or placebo (P < .05 and P < .01) and in patients treated with tramadol than in those treated with placebo (P < .05).
Conclusions As a pharmacologic means of preventing shivering in patients undergoing neuraxial anesthesia, nefopam may hold the greatest promise.
- Anesthetic techniques
- Epidural and subarachnoid
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Supported in part with departmental research funds, without a corporate sponsor.
Presented in part at the 9th Annual Meeting of the European Society of Anaesthesiologists, Gothenburg, Sweden, April 7-10, 2001.
None of the authors have a financial association with the manufacturer of nefopam or tramadol.